Products
Online Inquiry
Our Products Cannot Be Used As Medicines Directly For Personal Use.
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
Ponatinib (AP24534)
Cat No.
CEI-0260
Description
Ponatinib (AP24534) can inhibit abl, PDGFR-beta, VEGFR, FGFR1, Src with IC50 of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM.
CAS No.
943319-70-8
Molecular Weight
532.56
Purity
>99%
Storage
2 years at -20centigrade Powder
Targets
Abl, PDGFR-alpha, VEGFR2, FGFR1 Src
Molecular Formula
C29H27F3N6O
Chemical Name
3-(2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide
Solubility
DMSO 30 mg/mL Water
In vitro
As an oral multitargeted tyrosine kinase inhibitor(TKI), ponatinib (AP24534) is a novel multi-targeted kinase inhibitor thatpotently inhibits native and mutant BCR-ABL. In vitro, ponatinib also hasinhibitory activity against a set of kinases implicated in the pathogenesis ofother hematologic malignancies, including FLT3, KIT, fibroblast growth factorreceptor 1 (FGFR1), and platelet derived growth factor receptor alpha (PDGFR-alpha)with IC50 of 13, 13, 2, and 1 nmol/L. The potency and activity profile of ponatinib wasnext compared to sorafenib and sunitinib. Ponatinib can inhibit leukemic cell lines harboringmutations in FLT3, KIT, fibroblast growth factor receptor 1 (FGFR1), andplatelet derived growth factor receptor alpha (PDGFR-alpha) with IC50of 0.3 to 20 nM.
Download
Download Datasheet